CytoMed Therapeutics Ltd
NASDAQ:GDTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Country Average (11.4), the stock would be worth $-3.17 (433% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.4 | $0.95 |
0%
|
| Country Average | 11.4 | $-3.17 |
-433%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| SG |
C
|
CytoMed Therapeutics Ltd
NASDAQ:GDTC
|
11.2m USD | -3.4 | -3.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 715.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 21.4 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 22.8 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 17.3 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 27.9 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.8 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 11.6 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 108.4 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -83.5 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 14.7 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.6 |
| Median | 11.4 |
| 70th Percentile | 20.2 |
| Max | 6 440.7 |
Other Multiples
CytoMed Therapeutics Ltd
Glance View
CytoMed Therapeutics Ltd. operates as a biopharmaceutical company. The company employs 27 full-time employees The company went IPO on 2023-04-14. The firm is focused on harnessing its licensed proprietary technologies to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies, as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. The company is developing three product candidates: CTM-N2D, iPSC-gdNKT and CTM-GDT. CTM-N2D is its lead product candidate, and it consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. Its second product candidate, iPSC-gdNKT, utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. Its third product candidate, CTM-GDT, consists of expanded allogeneic gamma delta T cells.
